medigraphic.com
Instituto Nacional de Salud Pública

2009, Number 5

<< Back Next >>

salud publica mex 2009; 51 (5)

Infection, inflammation and gastric cancer.

Fuentes-Pananá E, Camorlinga-Ponce M, Maldonado-Bernal C

Language: Spanish
References: 54
Page: 427-433
PDF size: 140.07 Kb.


ABSTRACT

A strong association between persistent infection, chronic inflammation and cancer has been described. Helicobacter pylori is the main cause of gastric cancer, with 900 000 new cases yearly. Helicobacter colonization triggers the gastric epithelial cells to secret IL-8, a chemoattractant of immune cells, which persistently infiltrate the infected tissue. High levels of inflammatory cytokines are found, leading to loss of local homeostasis due to altered cell proliferation and apoptosis. It is not known how this local inflammatory response leads to cancer but the expression of mutagenic O2 and N2 free radicals might directly contribute to the irreversible mucosal genomic damage. Epstein Barr Virus is another pathogen associated with gastric cancer. We review here our current knowledge of inflammatory mechanisms at the site of infection that could be important to the development of cancer and that could be shared by other pathogens. This is of great importance since around 25% of cancers are associated with infection.


REFERENCES

  1. World Health Organization. World Cancer Day: Global action to avert 8 million cancer-related deaths by 2015. [Consultado 2008 noviembre 10]. Disponible en: http://www.who.int/mediacentre/news/releases/2006/pr06/ en/index.html.

  2. Instituto Nacional de Estadística, Geografía e Informática. Estadísticas a propósito del día mundial contra el cáncer. Datos Nacionales. [Consultado 2009 enero 12]. Disponible en: http://inegi.gob.mx/inegi/contenidos/ español/prensa/contenidos/estadisticas/2009/cancerO.doc

  3. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56(2):69-83.

  4. Correa P, Piazuelo MB, Camargo MC. Etiopathogenesis of gastric cancer. Scand J Surg 2006;95(4):218-224.

  5. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-490.

  6. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91(19):9131-9135.

  7. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-867.

  8. Stewart BW, Kleihues P. World Cancer Report. IARC Press, Lyon.

  9. Tovar-Guzman V, Hernandez-Giron C, Barquera S, Rodriguez-Salgado N, Lopez-Carrillo L. Epidemiologic panorama of stomach cancer mortality in Mexico. Arch Med Res 2001;32(4):312-317.

  10. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996;5(6):477-481.

  11. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9(Suppl 2):45-51.

  12. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 2008;99(9):1726-1733.

  13. Herrera-Goepfert R, Akiba S, Koriyama C, Ding S, Reyes E, Itoh T, et al. Epstein-Barr virus-associated gastric carcinoma: evidence of age-dependence among a mexican population. World J Gastroenterol 2005;11:6096-6103.

  14. Amsterdam K, Arnoud H, van Vliet M, Kusters JG, Arie van der E. Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev 2006;30:131-156.

  15. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Inter Med 2008;47:1077-1083.

  16. Amieva MR, El-Omar E. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008;134:306-323.

  17. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000;21(3):405-426.

  18. Pattengale PK, Smith RW, Gerber P. Selective transformation of B lymphocytes by E.B. virus. Lancet 1973;2(7820):93-94.

  19. Rickinson AB, Kieff E. Epstein-Barr virus. Virology. Philadelphia: Lippincott-Raven Publishers, 1996:2397-2446.

  20. Kieff E. Epstein-Barr virus and their replication. In: Fields BN, Knipe DM, Howley PM, (ed.). Virology. Philadelphia: Lippincott-Raven Publishers, 1996:2343-2396.

  21. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995;55(1):39- 45.

  22. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab- Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95(20):11963-11968.

  23. Allen MD, Young LS, Dawson CW. The Epstein-Barr virus-encoded LMP2A and LMP2b proteins promote epithelial cell spreading and motility. J Virol 2005;79(3):1789-1802.

  24. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG. The Epstein-Barr virus nuclear antigen-I promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A 2009;106(7):2313-2318.

  25. Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol 2002;2(10):725-734.

  26. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002;2(10):787-795.

  27. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801.

  28. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006;7(12):1250-1257.

  29. Delbridge LM, O’Riordan MX. Innate recognition of intracellular bacteria. Curr Opin Immunol 2007;19(1):10-16.

  30. Schmausser B, Andrulis M, Enrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004;136:521-526.

  31. Schmausser B, Andrulis M, Enrich S, Lee SK, Josenhans C, Müller- Hermelink HK. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295:179- 185.

  32. Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H, et al. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007;293(5):G1004-G1012.

  33. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19(1):3-10.

  34. Montero-Vega MT, De Andrés-Martín A. Toll-like receptors: a family of innate sensors of danger that alert and drive immunity. Allergol Immunopathol 2008;36(6):347-357.

  35. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005;6(12):1198-1205.

  36. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004;6(3):297-305.

  37. Li Q, Qithoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005;26(6):318-325.

  38. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol 2005;17(11):1367-1378.

  39. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117(5):1175-1183.

  40. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007;132(3):905-912.

  41. Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005;46(6):869-872.

  42. Trejo-de la O A, Torres J, Pérez-Rodríguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008;129(2):333-340.

  43. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn’s disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004;127(1):365-366.

  44. Sun J, Wiklund F, Hsu FC, Balter K, Zheng SL, Johansson JE, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15(3):480-485.

  45. Ando T, Goto Y, Maeda O, Watanabe O, Ishiguro K, Goto H. Causal role of Helicobacter pylori infection in gastric cancer. World J Gastroenterol 2006;12(2):181-186.

  46. Ishihara S, Rumi MA, Kadowaki Y, Ortega-Cava CF, Yuki T, Yoshino N, et al. Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol 2004; 173(2):1406-1416.

  47. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157(3):729-735.

  48. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, et al. Tolllike receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288(5):G1055-1065.

  49. Chang YJ, Wu MS, Lin JT, Sheu BS, Muta T, Inoue H, et al. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappa B activation. Mol Pharmacol 2004;66(6):1465-1477.

  50. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175(12):8242-8252.

  51. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004;5(11):1166-1174.

  52. Rad R, Brenner L, Krug A, Voland P, Mages J, Lang R, et al. Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori. Gastroenteroly 2007;133(1):150-163.

  53. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23(26):6370-6378.

  54. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-1571.




2020     |     www.medigraphic.com